Vise Technologies, Inc. Vir Biotechnology, Inc. Transaction History

Vise Technologies, Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 31, 2023	SELL	$9.14 - $24.62 $155,581 - $419,081	-17,022 Reduced 51.77%	15,861 $148,000
Q2 2023 Aug 08, 2023	SELL	$23.2 - $27.29 $43,801 - $51,523	-1,888 Reduced 5.43%	32,883 $806,000
Q1 2023 May 10, 2023	BUY	$22.26 - $30.85 $101,928 - $141,262	4,579 Added 15.17%	34,771 $809,000
Q4 2022 Feb 09, 2023	BUY	$19.96 - $28.22 $177,983 - $251,637	8,917 Added 41.91%	30,192 $764,000
Q3 2022 Nov 14, 2022	SELL	$18.26 - $31.1 $52,387 - $89,225	-2,869 Reduced 11.88%	21,275 $410,000
Q2 2022 Aug 15, 2022	BUY	$19.08 - $26.7 $460,667 - $644,644	24,144 New	24,144 $615,000

215

85.7M

127K

1.19M

Ticker VIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 132,638,000
Market Cap $1.33B
Description
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 fo...

Get notified when there are updates to the investment portfolio of Vise Technologies, Inc., based on Form 13F filings with the SEC.

Stay updated on Vise Technologies, Inc. with notifications on news.